Search results

NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments. This follows the government’s decision to increase the thresholds that NICE can use in technology appraisals to £25,000 to £35,000 per quality-adjusted life year gained.

Find out more about changes to NICE’s cost-effectiveness thresholds and the recent EQ-5D-5L public consultation.

Home What NICE does Our guidance Modular updates {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem"

Over the next year, our prioritisation decisions will be shaped by the government’s strategic direction for health and life sciences, and by the needs of the NHS, local systems and the people who use services.

Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

Home What NICE does Our guidance About interventional procedures guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElem

Home What NICE does Our guidance Prioritising our guidance topics Our prioritisation decisions...

Home What NICE does Our guidance About interventional procedures guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElem

Suggest a topic for our prioritisation process

NICE International enquiry form

The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.

These are the main stages in the multiple technology appraisal process used before April 2018.

We work with the clinical classifications service of NHS England to provide relevant clinical coding information for interventional procedures.

The key stages in development of our quality standards

Home What NICE does Our guidance About technology appraisal guidance Our methods and processes (health technology evaluation manual) Methods and...